The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Valproic acid: A viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures
Open accessAbstract
Various DNA methyl transferase inhibitors (iDNMTs) and histone deacetylase inhibitors (iHDACs) were screened for their ability to enhance transient gene expression (TGE) in Human Embryonic Kidney 293‐EBNA (HEK293E) cells. The effects in HEK293E cells were compared to those in Chinese Hamster Ovary DG44 (CHO‐DG44) cells. The iDNMTs and iHDACs were chosen based on their different cellular activities and mechanisms of action. For each inhibitor tested, the optimum concentration was determined for both cell lines, and these conditions were used to evaluate the effect of each compound using a recombinant monoclonal antibody as a reporter protein. All the iHDACs increased transient antibody yield at least 4‐fold in HEK293E and at least 1.5‐fold in CHO‐DG44. By comparison, the iDNMTs increased antibody yields by a maximum of ∼2‐fold. Pairwise combinations of iDNMTs and iHDACs had a linearly additive effect on TGE in CHO‐DG44 but not in HEK293E. With valproic acid (VPA), volumetric and specific productivities of 200 mg/L and 20 pg/cell/day, respectively, were achieved in HEK293E cells with a 10‐day process. As VPA is both FDA‐approved and 5‐fold less expensive than sodium butyrate (NaBut), we recommend it as a cost‐effective alternative to this widely used enhancer of recombinant protein production from mammalian cells. Biotechnol. Biotechnol. Bioeng. 2008;101: 182–189. © 2008 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Self-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Inhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523
Large-Scale transfection of mammalian cells for the fast production of recombinant protein
Pham, P. L., Kamen, A., & Durocher, Y. (2006) · Molecular Biotechnology · doi:10.1385/mb:34:2:225 · Cited by 236
Cited by
Screening and large-scale expression of membrane proteins in mammalian cells for structural studies
Goehring, A., Lee, C.-H., Wang, K. H., Michel, J. C., Claxton, D. P., Baconguis, I., Althoff, T., Fischer, S., Garcia, K. C., & Gouaux, E. (2014) · Nature Protocols · doi:10.1038/nprot.2014.173 · Cited by 726
Growth Factors Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing
Martino, M. M., Briquez, P. S., Güç, E., Tortelli, F., Kilarski, W. W., Metzger, S., Rice, J. J., Kuhn, G. A., Müller, R., Swartz, M. A., et al. (2014) · Science · doi:10.1126/science.1247663 · Cited by 498
Expression of Recombinant Antibodies
Frenzel, A., Hust, M., & Schirrmann, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00217 · Cited by 353
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Ritacco, F. V., Wu, Y., & Khetan, A. (2018) · Biotechnology Progress · doi:10.1002/btpr.2706 · Cited by 273
Metadata
- Authors
- Backliwal, G., Hildinger, M., Kuettel, I., Delegrange, F., Hacker, D. L., & Wurm, F. M.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2008-05-02
- Volume
- 101
- Issue
- 1
- Pages
- 182-189
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2117471612
- Cited by
- 170
- References
- 5
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.